Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1991-4-30
|
pubmed:abstractText |
A study is currently underway to investigate the efficacy of interferon therapy in patients with prolonged (greater than or equal to 10 weeks but less than 6 months) hepatitis B infection. To date, a total of 15 patients have been enrolled in the study and randomly assigned to receive either placebo for 24 weeks (n = 8) or interferon 5 million units subcutaneously 3 times a week for 24 weeks (n = 7), with follow up for 1 year. Thirteen patients have completed the follow-up period: seven patients in the placebo group and six in the treated group. Five of the six treated patients completely eradicated the infection during interferon therapy, with clearance of hepatitis B e and surface antigens, and seroconversion to antibody positivity in each case. Two of the eight placebo patients seroconverted during the placebo period. Clearance of hepatitis B e antigen was associated with a sudden rise in serum transaminase levels and an exacerbation of hepatitis, a phenomenon that has also been reported in chronic hepatitis B patients who have responded well to interferon therapy. Therapy was well tolerated in all cases. Our results suggest that interferon treatment of patients with prolonged hepatitis B infection may prevent progression to chronicity. If confirmed by further study, they should trigger more vigilant screening for patients with raised serum transaminase levels and viral markers of hepatitis B infection.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Core Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B e Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M,
http://linkedlifedata.com/resource/pubmed/chemical/Interferons,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotide Probes
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0168-8278
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S95-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1706741-Base Sequence,
pubmed-meshheading:1706741-Chronic Disease,
pubmed-meshheading:1706741-DNA, Viral,
pubmed-meshheading:1706741-Follow-Up Studies,
pubmed-meshheading:1706741-Hepatitis B,
pubmed-meshheading:1706741-Hepatitis B Core Antigens,
pubmed-meshheading:1706741-Hepatitis B Surface Antigens,
pubmed-meshheading:1706741-Hepatitis B e Antigens,
pubmed-meshheading:1706741-Hepatitis B virus,
pubmed-meshheading:1706741-Humans,
pubmed-meshheading:1706741-Immunoglobulin M,
pubmed-meshheading:1706741-Interferons,
pubmed-meshheading:1706741-Molecular Sequence Data,
pubmed-meshheading:1706741-Oligonucleotide Probes,
pubmed-meshheading:1706741-Polymerase Chain Reaction
|
pubmed:year |
1990
|
pubmed:articleTitle |
Possible prevention of chronic hepatitis B by early interferon therapy.
|
pubmed:affiliation |
Service d'Hépatogastroentérologie, Hôtel Dieu, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|